Literature DB >> 16892404

Enzyme isoselective inhibitors: application to drug design.

Michael Shokhen1, Netaly Khazanov, Amnon Albeck.   

Abstract

Common methodologies of computer-assisted drug design focus on noncovalent enzyme-ligand interactions. We introduced enzyme isoselective inhibition trend analysis as a tool for the expert analysis of covalent reversible inhibitors. The methodology is applied to predict the binding affinities of a series of transition-state analogue inhibitors of medicinally important serine and cysteine hydrolases. These inhibitors are isoselective: they have identical noncovalent recognition fragments (RS) and different reactive chemical fragments (CS). Furthermore, it is possible to predict the binding affinities of a series of isoselective inhibitors toward a prototype enzyme and to extrapolate the data to a target medicinally important enzyme of the same family. Rational design of CS fragments followed by conventional RS optimization could be used as a novel approach to drug design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16892404     DOI: 10.1002/cmdc.200600030

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  3 in total

1.  EMBM - a new enzyme mechanism-based method for rational design of chemical sites of covalent inhibitors.

Authors:  Tamar Traube; Subramaniam Vijayakumar; Michal Hirsch; Neta Uritsky; Michael Shokhen; Amnon Albeck
Journal:  J Chem Inf Model       Date:  2010-11-19       Impact factor: 4.956

2.  Differentiating serine and cysteine protease mechanisms by new covalent QSAR descriptors.

Authors:  Michael Shokhen; Tamar Traube; Subramaniam Vijayakumar; Michal Hirsch; Neta Uritsky; Amnon Albeck
Journal:  Chembiochem       Date:  2011-03-24       Impact factor: 3.164

3.  Challenging a paradigm: theoretical calculations of the protonation state of the Cys25-His159 catalytic diad in free papain.

Authors:  Michael Shokhen; Netaly Khazanov; Amnon Albeck
Journal:  Proteins       Date:  2009-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.